Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

2-Year U.S. Treasury Note Continuous Contract $102.695-0.027-0.03% 5-Year U.S. Treasury Note Continuous Contract $106.398-0.063-0.06% 10-Year U.S. Treasury Note Continuous Contract $109.156-0.078 ...